Investing.com — Compass Pathways plc (NASDAQ: CMPS )，一家专注于开发精神病治疗方法的制药公司，市值为2.78亿美元，根据最近的SEC文件，该公司宣布对其财务和执行结构进行重大调整。根据 InvestingPro ...

Investing.com — 周五，Stifel分析师维持了对Compass Pathways（NASDAQ:CMPS）股票的买入评级，目标价保持在11.00美元不变，相比当前2.70美元的价格有显著上涨空间。根据 InvestingPro 数据，分析师目标价范围在11美元至45美元之间，表明这家市值2.5亿美元的公司具有巨大的潜在上涨空间。此次评级确认是在最近与Compass ...

Compass COMP shares have gained 28.4% year to date, outperforming the Zacks Computer and Technology sector and the Internet - Software industry’s declines of 14.4% and 10.9%, respectively.

LONDON & NEW YORK, March 26, 2025--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced the ...

Compass Therapeutics (NASDAQ:CMPX) stock gains as its oncology drug tovecimig hits main goal in a Phase 2/3 trial for biliary tract cancer. Read more here.

Detailed price information for Compass Inc Cl A (COMP-N) from The Globe and Mail including charting and trades.

Leerink Partnrs upgraded shares of Compass Therapeutics (NASDAQ:CMPX – Free Report) from a hold rating to a strong-buy rating in a research note released on Tuesday morning,Zacks.com reports.

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced the completion of recruitment in the COMP005 phase 3 ...

Leerink Partners upgraded shares of Compass Therapeutics (NASDAQ:CMPX – Free Report) from a market perform rating to an outperform rating in a research report report published on Wednesday, MarketBeat ...

About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by ...

LONDON & NEW YORK, March 26, 2025--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today ...